Últimas noticias sobre Schmid Group (NASDAQ:SHMD) Bolsa

Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

SCHMID Group N.V. - Class A Ordinary Shares

Schmid Group NV

Shimano Inc

<a href="https://www.dallasfed.org/banking/events/2025/25banking" title="https://www.dallasfed.org/banking/events/2025/25banking">https://www.dallasfed.org/banking/events/2025/25banking</a>

Macro Economic Events

News

Economics

Federal Reserve

Fed's Logan Says Key Risk Is If Higher Short-term Inflation Expectations Become Entrenched; Our Job Is To Ensure Inflation Doesn't Become Persistent; Risks From Tariffs Is For Higher Unemployment And Higher Inflation, Putting Two Fed Goals In Conflict

Options

Markets

Trading Ideas

QBTS

D-Wave Quantum Option Alert: Fri $18 Calls Sweep (43) near the Ask: 1904 @ $0.349 vs 5295 OI; Ref=$16.13

WIIM

DKNG

FLUT

PENN

WYNN

Shares of sports betting and gambling stocks are trading lower following the state of Illinois's decision to adopt a tax hike on sports betting.

Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $171 to $215.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Tenet Healthcare, Raises Price Target to $215

Applied Industrial Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) has outperformed the market over the past 5 years by 14.23% on an annualized basis producing an average annual return of 27.17%. Currently, Applied Industrial Techs has a market capitalization of $8.69 billion. 
Buying $100 In AIT: If an investor had bought $100 of AIT stock 5 years ago, it would be worth $347.84 today based on a price of $226.52 for AIT at the time of writing.
<h3>Applied Industrial Techs's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748874617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Applied Industrial Techs Stock In The Last 5 Years

RBC Capital analyst Michael Carroll maintains Easterly Government Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>) with a Underperform and lowers the price target from $27.5 to $22.

RBC Capital Maintains Underperform on Easterly Government Props, Lowers Price Target to $22

FANG

MTDR

SHEL

Shares of oil stocks are trading higher amid an OPEC+ decision to keep output levels unchanged.

Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">STAT6 degrader medicine</a>.
The findings significantly surpassed the company&#8217;s expectations, demonstrating robust STAT6 degradation and a favorable safety profile, thereby derisking the program, the company said in a press release.
Pharmacokinetics (PK):
KT-621 demonstrated a favorable <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45717730/kymera-therapeutics-announces-positive-first-in-human-results-from-phase-1-healthy-volunteer-clini" rel="noreferrer noopener">plasma PK profile</a> after single and multiple doses. Rapid absorption was demonstrated with a median tmax&nbsp;of 2-4 hours and a mean half-life of 9-36 hours. There was a dose-proportional increase in exposure after multi-dosing, and a steady state was achieved by Day 4.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45719840/modernas-new-covid-vaccine-secures-fda-clearance-for-seniors-at-risk-individuals" rel="noreferrer noopener">Moderna&#8217;s New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals</a>
Pharmacodynamics (PD):
KT-621 demonstrated rapid, deep, and prolonged STAT6 degradation in blood after single doses of KT-621 and in blood and skin after multiple doses of KT-621.
STAT6 levels in blood and skin were measured. Complete degradation within a cohort is defined as either a mean reduction of ≥95% or, when most subjects&#8217; STAT6 levels are reduced below the Lower Limit of Quantification (LLOQ), or both.
In SAD, maximal degradation was achieved in blood as quickly as the first collected timepoint of 4 hours after a single dose, with mean STAT6 degradation reaching &gt;90% across all SAD doses starting at 6.25 mg.
All SAD cohorts at 75 mg or greater doses achieved &gt;95% mean STAT6 degradation with STAT6 levels below LLOQ in multiple subjects.
In MAD, STAT6 degradation was observed in blood at the first timepoint measured (8 hours) for doses above 1.5 mg.
Steady-state, complete degradation, associated with STAT6 reductions below the LLOQ in the majority of subjects, was achieved at doses ≥50 mg, with recovery starting as early as 4 days after the last dose.
In MAD, robust STAT6 degradation was observed in the skin at the first timepoint measured (Day 7) for doses above 1.5 mg.
Steady-state, complete degradation, associated with ≥95% mean STAT6 degradation with STAT6 levels below LLOQ in multiple subjects, was achieved at doses ≥50 mg.
Th2 Biomarkers:
TARC reduction was observed for all KT-621 dose groups, with a median reduction of up to 37% at Day 14.
The company says the results are comparable or superior to what was seen in the Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)/Regeneron Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Dupixent (dupilumab) healthy volunteer study.
The safety profile of KT-621 was undifferentiated from that of the placebo.
The company&#8217;s KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis patients is ongoing, with data expected to be reported in the fourth quarter of 2025. 
Two parallel Phase 2b trials in atopic dermatitis and asthma will start in 4Q25 and 1Q26, respectively.
Price Action: KYMR stock was trading higher by 30.2% to $38.58 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45720783/kidney-health-focused-vera-therapeutics-stock-price-spikes-on-heels-of-successful-trial-data" target="_blank" rel="noreferrer noopener">Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Movers

General

KYMR

REGN

Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response

RVYL

Ryvyl Shares Resume Trade Following Circuit Breaker Halt

Barclays analyst Andrew Mok maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Equal-Weight and lowers the price target from $362 to $351.

Barclays Maintains Equal-Weight on Molina Healthcare, Lowers Price Target to $351

Guardian Pharmacy Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) on Monday announced its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45719054/guardian-pharmacy-services-expands-pacific-northwest-footprint-with-acquisition-of-washington-base" rel="noreferrer noopener">entry into the Pacific Northwest market</a> through the acquisition of Mercury Pharmacy Services, a Mountlake Terrace-based provider of long-term care (LTC) pharmacy solutions.
The move strengthens Guardian's national presence and addresses the growing demand for LTC support in Washington state, the company said in a press release.
The financial terms of the deal, one of Guardian&#8217;s larger recent single-pharmacy acquisitions, were not disclosed.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45720783/kidney-health-focused-vera-therapeutics-stock-price-spikes-on-heels-of-successful-trial-data" rel="noreferrer noopener">Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data</a>
The deal brings a well-established operation serving assisted living, skilled nursing, behavioral health, and disability care communities across the Seattle-Tacoma region.
Fred Burke, Guardian's CEO, said the company seeks high-performing local partners in regions with unmet needs. He highlighted Mercury's strong market reputation as a natural fit for Guardian's expansion goals.
Mercury, founded in 2001, will retain its name and staff, continuing operations under Guardian's ownership. The company will also gain access to Guardian's centralized resources, including IT, analytics, and HR support, enabling its team to focus on patient care and service delivery.
Founded in 2004, Guardian now operates over 50 pharmacies serving more than 7,000 LTC facilities nationwide, growing through a mix of acquisitions, startups, and organic development.
GRDN held <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45359262/guardian-pharmacy-services-inc-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">cash and cash equivalents</a> of $14 million as of March 31, 2025.
Related ETFs: Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>), iShares U.S. Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>).
Price Action: GRDN shares closed lower by 1.03% at $21.17 on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45719179/sanofi-expands-rare-immunology-portfolio-with-blueprint-buyout" target="_blank" rel="noreferrer noopener">Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout</a></li>
</ul>
Image via Shutterstock

GRDN

iShares Trust Dow Jones US Healthcare Sector Index Fund

Guardian Pharmacy Strengthens US Footprint With New Seattle-Area Acquisition

<a href="https://capitolnewsillinois.com/news/new-taxes-on-sports-bets-nicotine-products-as-democrats-pass-55-2b-budget/" title="https://capitolnewsillinois.com/news/new-taxes-on-sports-bets-nicotine-products-as-democrats-pass-55-2b-budget/">https://capitolnewsillinois.com/news/new-taxes-on-sports-bets-nicotine-products-as-democrats-pass-55-2b-budget/</a>

CHDN

GAMB

Reported June 1, 2025: 'New Taxes On Sports Bets, Nicotine Products As Democrats Pass $55.2B Budget' - Capital News Illinois

Science Applications International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) stock is trading lower on Monday after reporting <a href="https://www.benzinga.com/pressreleases/25/06/g45717713/saic-announces-first-quarter-of-fiscal-year-2026-results">the first-quarter 2026 earnings</a>.
The company reported&nbsp;quarterly sales growth&nbsp;of 2% year-on-year to $1.88 billion, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate</a> of $1.87 billion.
The adjusted EPS of $1.92&nbsp;missed the analyst consensus&nbsp;estimate of $2.22.
Also Read: <a href="https://www.benzinga.com/markets/large-cap/25/06/45720002/campbells-brews-up-strong-q3-beats-estimates-as-home-cooking-sector-simmers">Campbell&#8217;s Brews Up Strong Q3: Beats Estimates As Home Cooking Sector Simmers</a>
Operating income for the quarter declined by 8% to $121 million, and the operating margin declined by 70 basis points to 6.4%.
Adjusted EBITDA decreased 5% to $157 million with an adjusted EBITDA margin of 8.4%, a 60 basis points decline.
Net bookings for the quarter were approximately $2.4 billion, which reflects a book-to-bill ratio of 1.3.&nbsp;
The quarter&#8217;s operating cash flow totaled $100 million. Free cash flow was an outflow of $44 million.
SAIC&#8217;s estimated backlog for the quarter was approximately $22.3 billion, of which $3.3 billion was funded. As of May 2, 2025, the company held $47 million in cash and equivalents.
CEO Toni Townes-Whitley acknowledged the steady progress it made against its enterprise growth strategy despite a still dynamic operating environment.
Science Applications <a href="https://www.benzinga.com/25/03/44355022/science-applications-q4-earnings-crush-estimates-helped-by-new-contract-volume" target="_blank" rel="noreferrer noopener">reiterated the 2026</a> revenue outlook of $7.60 billion-$7.75 billion, below the analyst consensus estimate of $7.93 billion.
The company maintained an annual adjusted EPS outlook of $9.10-$9.30 below the <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst consensus estimate</a> of $10.24.
Price Action: SAIC shares are trading lower by 10.7% to $103.21 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45716922/taiwan-semiconductor-eyes-uae-gigafab-seeks-crucial-us-green-light" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Eyes UAE Gigafab, Seeks Crucial US Green Light</a></li>
</ul>
Photo by DCStockPhotography via Shutterstock

Earnings

Guidance

Tech

SAIC

SAIC Stock Falls After Q1 Earnings Miss, Soft Guidance

Rivian Automotive, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) stock traded lower Monday by about 2.86% after the electric vehicle company announced plans to offer $1.25 billion in senior secured green notes due 2031 in <a href="https://www.benzinga.com/pressreleases/25/06/b45717976/rivian-automotive-inc-announces-proposed-1-25-billion-senior-secured-green-notes-offering-to-refin" target="_blank" rel="noreferrer noopener">a private offering</a>.
The EV manufacturer plans to use the offering proceeds and cash on hand to redeem $1.25 billion of outstanding floating rate senior secured notes due 2026 and pay related fees and expenses.
Rivian held $7.2 billion in <a href="https://www.benzinga.com/pressreleases/25/05/b45235082/rivian-releases-first-quarter-2025-financial-results" target="_blank" rel="noreferrer noopener">cash and equivalents</a> as of March 31.
Also Read: <a href="https://www.benzinga.com/25/04/44934176/rivian-taps-ai-expert-aidan-gomez-to-drive-innovation-advanced-technology-integration" target="_blank" rel="noreferrer noopener">This Tesla Rival Taps AI Expert Aidan Gomez To Drive Innovation</a>
Riavian stock is up close to 10% year-to-date and over 27% in the last 12 months.
Rivian had a better-than-expected <a target="_blank" href="https://www.benzinga.com/25/05/45642153/rivian-ceo-rj-scaringe-touts-45000-rivian-r2s-updated-rear-suspension-cant-wait-for-folks" rel="noreferrer noopener">first quarter 2025</a>, reporting quarterly revenue of $1.24 billion, a 3% increase. However, Rivian&nbsp;slashed its delivery projections&nbsp;for 2025 amid tariff uncertainty, which could raise the company&#8217;s cost per vehicle.
Rivian CEO RJ Scaringe had <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45617151/ubs-maintains-neutral-rating-for-rivian-stock-sets-price-13-price-target" target="_blank" rel="noreferrer noopener">voiced the company&#8217;s</a> plans for the R2, which is seen as an affordable option in Rivian&#8217;s otherwise costly line-up of SUVs and Pickup trucks.
The car maker also expanded its facility in Normal, Illinois, with a $120 million investment, which could create hundreds of jobs as the company reaffirmed its U.S.-centric supply chain.
CNBC&#8217;s Jim Cramer&nbsp;said&nbsp;Rivian <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45562808/jim-cramer-rivian-better-than-this-automaker-pan-american-silver-is-the-best-silver-mine" target="_blank" rel="noreferrer noopener">is better than</a>&nbsp;Lucid Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>).
Price Action: Rivian shares are trading lower at aruond $14.12 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45717955/chinas-nio-clocks-13-deliveries-growth-in-may-tesla-lags" target="_blank" rel="noreferrer noopener">China&#8217;s NIO Clocks 13% Deliveries Growth In May, Tesla Lags</a></li>
</ul>
Image: Shutterstock

Bonds

Offerings

LCID

RIVN

Rivian Stock Goes Red After Offering $1.25 Billion Green Bond To Refinance 2026 Debt

Barclays analyst Andrew Mok maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and lowers the price target from $322 to $273.

Barclays Maintains Equal-Weight on Humana, Lowers Price Target to $273

VivoPower to leverage BitGo's best-in-class OTC trading desk and custody platform to build digital asset treasury strategy
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- BitGo, the leading infrastructure provider of digital asset solutions, and VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>, "VivoPower"))), a publicly traded company that recently announced transition to an XRP focused treasury and decentralized finance solutions company, today announced a strategic partnership. VivoPower, having successfully raised US$121 million, will leverage BitGo as an exclusive over-the-counter (OTC) trading desk to acquire XRP for its initial US$100 million acquisition of XRP tokens.
VivoPower will exclusively leverage BitGo for both the trading of its XRP holdings through BitGo's 24/7/365 OTC trading desk and holding of its assets through BitGo's best-in-class custody platform. As a result, VivoPower is expected to benefit from BitGo's liquidity, robust execution capabilities, and secure cold storage infrastructure.

VVPR

VivoPower Forms Strategic Partnership With BitGo To Launch $100M XRP Acquisition And Digital Asset Treasury Strategy Using BitGo's Premier OTC Trading Desk and Custody Platform

Barclays analyst Andrew Mok maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Overweight and raises the price target from $366 to $416.

Barclays Maintains Overweight on HCA Healthcare, Raises Price Target to $416

<a href="https://www.dallasfed.org/banking/events/2025/25banking">https://www.dallasfed.org/banking/events/2025/25banking</a>
&nbsp;
&nbsp;

Fed's Logan Says Despite Uncertainty, Financial Market Volatility, Us Economy Is Resilient; Labor Market Is Stable; Inflation Still Somewhat Above Target; Risks Are Balanced On Both Sides Of Mandate; If Tariffs Change Inflation Expectations That Would Be Significant; Market Volatility, Uncertainty Could Cause Households, Businesses To Pull Back; Monetary Policy Well Positioned To Wait, Be Patient; Well-Positioned To Act If Risks Materialize

Uranium Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UEC#AMEX">UEC</a>) reported quarterly losses of $(0.07) per share. This is a 40 percent decrease over losses of $(0.05) per share from the same period last year.

Uranium Energy Q3 EPS $(0.07) Down From $(0.05) YoY

Barclays analyst Andrew Mok maintains Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) with a Overweight and lowers the price target from $522 to $480.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $480

Press Releases

SCHMID Group Update on Order Situation and Market Development in 2025

SHMD

Benchmark Electronics

Celestica

Data I/O

Deswell Indus

Flex

Fabrinet

IPG Photonics

Jabil

Kimball Electronics

Key Tronic

Methode Electronics

Neonode

Nortech Systems Incorporated - Common Stock

Nortech Systems

Syntec Optics Holdings, Inc. - Class A Common Stock

Syntec Optics Holdings

Plexus

RF Industries

Sanmina

SigmaTron International, Inc. - Common Stock

Sigmatron Intl

Schmid Group

TE Connectivity

Tungray Technologies Inc - Class A Ordinary Shares

Comments

Schmid Group

Noticias

Últimas noticias sobre Schmid Group (NASDAQ:SHMD) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL